ACADIA Pharmaceuticals Inc. — Q2 2016 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2016; comparative periods ended June 30, 2015. Amounts below are in U.S. dollars unless noted.
Business context
ACADIA is a biopharmaceutical company focused on central nervous system disorders. FDA approved its first drug, NUPLAZID (pimavanserin), on April 29, 2016, for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP); U.S. prescriptions began May 31. The company is beginning commercialization while continuing development of pimavanserin for additional indications.
Key financial metrics
| Metric | Q2 2016 | Six months 2016 | Comparable 2015 |
|---|---|---|---|
| Total revenue | $97,000 | $101,000 | $1,000 quarter; $5,000 six months |
| Net product sales | $97,000 | $97,000 | None |
| Research and development | $20.5 million | $43.3 million | $18.4 million quarter; $34.7 million six months |
| Selling, general and administrative | $50.8 million | $78.3 million | $21.1 million quarter; $45.4 million six months |
| Operating loss | $71.9 million | $122.2 million | $39.5 million quarter; $80.0 million six months |
| Net loss | $71.3 million | $121.1 million | $39.4 million quarter; $79.8 million six months |
| Net loss per share, basic and diluted | $0.63 | $1.08 | $0.39 quarter; $0.80 six months |
| Net cash used in operating activities | Not separately provided | $98.0 million | $55.2 million six months |
Q2 cost of product sales was $526,000, or approximately 542% of product sales, reflecting manufacturing and other period costs not directly tied to sales volume; product gross margin was therefore negative during this early launch period. The company also recorded $248,000 of license fees and royalties, including amortization of the NUPLAZID-related milestone asset. Revenue recognition uses a sell-through model; $513,000 of product revenue was deferred at quarter-end.
At June 30, cash and cash equivalents were $131.8 million and available-for-sale investments were $280.8 million, totaling $412.6 million, versus $215.1 million at December 31, 2015. Current assets were $423.9 million and current liabilities $29.0 million. No borrowings or material debt are reported in the supplied filing text; long-term liabilities were $197,000. Stockholders’ equity was $408.8 million. The six-month cash-flow statement reports $176.2 million used in investing and $303.7 million provided by financing, including stock issuance proceeds and a settlement payment.
Material changes versus prior periods
- Commercial launch began after FDA approval, but recognized sales remained minimal in the first weeks of availability.
- Q2 SG&A rose to $50.8 million from $21.1 million, primarily due to launch preparation, medical education, external services and hiring a specialty sales force of about 135 representatives.
- Six-month R&D increased to $43.3 million from $34.7 million, reflecting personnel and clinical-development costs, partly offset by lower manufacturing-development costs.
- Cash and investments increased by $197.5 million from year-end, chiefly following a January 2016 public offering that raised approximately $281.6 million net. The company also received $14.3 million under a stockholder settlement, recorded as a capital contribution.
- Common shares outstanding increased from 101.9 million at year-end to 113.7 million at June 30. The filing reports 114.0 million shares outstanding as of July 29.
Outlook, commentary and risks
- Management expects operating losses and substantial R&D and commercialization spending to continue for at least the next few years. It expects existing cash, cash equivalents and investments to fund planned operations for at least the next 12 months; future financing may still be required.
- Management expects increased costs for the NUPLAZID launch, post-marketing studies and development in additional indications. It expects top-line results from the Phase II Alzheimer’s disease psychosis study by year-end 2016 and planned to initiate a Phase II Alzheimer’s agitation study in the second half of 2016. No revenue, earnings or other quantified financial guidance is provided.
- Key commercial risks include uncertain market adoption, diagnosis rates, payer coverage and reimbursement, pricing, adherence, and the product’s boxed warning. The company cautions that launch success and market potential are uncertain.
- FDA post-marketing commitments include additional PDP and safety studies. Negative findings or noncompliance could lead to labeling changes, restrictions or withdrawal of approval. European filing timing was pushed back while the company worked with the EMA on a pediatric investigation plan; no revised filing date was given.
- ACADIA relies on one supplier each for NUPLAZID active ingredient and finished drug product. Supply interruption, quality or regulatory issues could impair commercialization. The company also has a consolidated securities class action pending; the motion to dismiss was under submission, and possible losses could not be estimated.
- Cost of product sales and license fees include launch-period items; the $8.0 million Ipsen milestone was capitalized and is being amortized through 2021. Management says disclosure controls were effective as of June 30, while implementation of commercial sales, inventory and cost processes materially changed internal controls over financial reporting.
Important facts for investors to verify
- Whether NUPLAZID prescriptions, sell-through revenue and payer access grow sufficiently to support the commercial investment.
- Cash burn relative to the stated runway, including launch, clinical and post-marketing commitments.
- Results and timelines for Alzheimer’s studies, FDA-required post-marketing studies and the EMA pediatric plan.
- Supply continuity with the single API and finished-product manufacturers, and any emerging safety or labeling developments.
- Status and potential financial exposure of the securities litigation, which the company had not quantified.